Schizophrenia/Psychosis

Importantly for lay and clinician readers alike, the book Monkey Mind: A Memoir of Anxiety reads as humor-laced triumph with many lost battles along the way rather than enduring unrelenting tragedy.

In schizophrenia therapy, perphenazine can play in combating symptoms and in preventing relapse, though it can be associated with metabolic side effects.

Evidence suggests that cannabis is associated with an increased risk of psychosis when it is used frequently. Marijuana doesn't count, does it?

Here: nutritional supplements and over-the counter medications in schizophrenia management.

In this video, international expert on schizophrenia, Peter F. Buckley, MD, gives an overview of what's new in schizophrenia and discusses the state-of-the-art of diagnosis and management of this complex and challenging disorder.

In light of our problems and uncertainties about the state of current psychiatry, or perhaps because of them, what might describe good psychiatry? Following are some suggestions for what we, as psychiatrists, can do.

Here: an unforgettable tale about schizophrenia and its impact on one girl's family.

An increasing number of patients are being brought to the emergency room because of bath salts and/or herbal incense toxicity.

It is important for the inpatient psychiatrist to understand the perspective of the newly admitted patient. Many patients will find the experience depersonalizing, threatening, and socially alienating and may perceive it as a personal failure.

The Suicide Risk Screening Alert is a clinical tool that assists the psychiatrist and nonpsychiatric physician in identifying patients at risk for suicide during brief medication management appointments.

Ongoing shortages of several psychotropic medications have wreaked havoc among patients and their families, caused frustration and reluctant prescription switches among physicians, and prompted investigations by Congress.

Dr Michael Thase touches on an APA presentation about newer applications of cognitive therapy for disorders such as schizophrenia and bipolar disorder.

Staying empathic and keeping the conflict within the patient instead of between the patient and health care provider, is a key to successful management.

The trouble with answering this question is that I couldn’t – and still can’t – recall the “best” memory. What much more readily came to mind are some of the worst memories.

The paradigm for modern psychiatry is evidence-based medicine (EBM)-it represents proven treatments for defined diagnoses. But there are major problems with this position, starting with the fact that while they are superior to placebo, evidence-based treatments too often are ineffective.

In a recent interview on 60 Minutes, Harvard psychologist Irving Kirsch, PhD, commented, “the difference between the effect of a placebo and the effect of an antidepressant is minimal for most people.”

Much could be gained if an agreed minimum set of appropriate and important outcomes was measured and reported in all clinical trials in a particular area.

Insight can be assessed in the course of a typical evaluation or follow-up interview with augmentation by questions borrowed from any of the validated insight rating scales.

When thinking about recent advances in psychopharmacology, we often point to new molecules with similar mechanisms of action but with better safety and tolerability profiles, or to molecules with novel mechanisms that effect positive change greater than that with existing treatments.

Adequate treatment of the underlying psychiatric illness consistently appears to be the most effective use of medication in suicidal patients.

Several studies have been undertaken to test the efficacy of drugs in the management of aggression and hostility in patients with schizophrenia and other mood disorders.

He wasn’t the first person I met days before I was to start my psychiatric residency, but as I walked about in my new city, he caught my attention much more than most. As psychiatrists, we typically assume that we will hear the inside stories, even if in bits and pieces, that will help us better understand and help patients. But perhaps we are too expectant . . .

With several good presentations going on today at EPA 2012, the hardest part was deciding which to attend. The sessions started at 8 this morning, and I decided to go to the Treating Schizophrenia Beyond Antipsychotic Drugs: Cognitive and Metacognitive Interventions.

Does an early diagnosis of schizophrenia really make a clinical difference?

Three twin studies published between 1977 and 1995, which provided the main body of knowledge on heritability of autism, showed a concordance rate of 72% for a total of 36 monozygotic pairs and a concordance rate of 0% for 30 dizygotic pairs.